Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8657265 | 0.89 | P2RX7 (0.36) | SMN1; SMN2SLC6A2SLC6A4SLC6A3TP53 | |
| SCHEMBL6482338 | 0.87 | UTS2R (0.40) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6475217 | 0.86 | UTS2R (0.39) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6473622 | 0.85 | UTS2R (0.39) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6482275 | 0.84 | UTS2R (0.38) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6474509 | 0.82 | UTS2R (0.38) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8650624 | 0.80 | ADRA1D (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6476257 | 0.79 | UTS2R (0.38) | UTS2RALDH1A1NPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6475209 | 0.79 | KMT2A (0.36) | ALDH1A1NPSR1 | |
| SCHEMBL7958038 | 0.77 | GPR88 (0.42) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | UTS2R 2236/4885ALDH1A1 792/4885NPSR1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.